Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Phase 3b Study to Evaluate the Long-Term Efficacy and Safety of Lerodalcibep in Children and Adolescents, 6 to 17 Years of Age, With Heterozygous Familial Hypercholesterolemia (LIBerate-Kids OLE)

NCT07775339 is registered in ClinicalTrials.gov with LIB Therapeutics LLC as lead sponsor.

NCT NCT07775339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07775339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Phase 3b Study to Evaluate the Long-Term Efficacy and Safety of Lerodalcibep in Children and Adolescents, 6 to 17 Years of Age, With Heterozygous Familial Hypercholesterolemia (LIBerate-Kids OLE)
Lead sponsor
LIB Therapeutics LLC
Phase
Phase 3
Overall status
Not yet recruiting
Start date
January 20, 2027
Completion date
December 31, 2031
Enrollment
150 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

heterozygous familial hypercholesterolemia (hefh)